<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Chronic granulocytic leukemia (CGL), Ph + is a chronic myeloproliferative disorder, which, due to its specificity for many decades, has attracted the attention of researchers of specialties. This disease was among the first malignant haemopathies that received their “ID card” since molecular precisely defined the basic pathological substrate, that origin of the disease. Over the past decades we have witnessed the evolution of the therapeutic approach in the treatment of from oral cystostatic therapy, radiotherapy, through recombinant interferon alpha (IFN-alpha), haematopoeza stem cell transplantation, to the targeted molecular therapy of the tyrosine inhibitor (TKI).</p>
<p>In this report we present patient with a diagnosis of Ph + in the early chronic phase at the age of 13 all relevant analyzes. During the past 26 years, all modalities of CGL treatment were applied in patients, according to the time period, concluding with the second generation resulting in complete remission of diseases with excellent quality of life and identical expectations for the future, as well as in healthy population.</p>
</abstract>

Chronic granulocytic leukemia (CGL), Ph + is a chronic myeloproliferative disorder, which, due to its specificity for many decades, has attracted the attention of researchers of specialties. This disease was among the first malignant haemopathies that received their “ID card” since molecular precisely defined the basic pathological substrate, that origin of the disease. Over the past decades we have witnessed the evolution of the therapeutic approach in the treatment of from oral cystostatic therapy, radiotherapy, through recombinant interferon alpha (IFN-alpha), haematopoeza stem cell transplantation, to the targeted molecular therapy of the tyrosine inhibitor (TKI).
In this report we present patient with a diagnosis of Ph + in the early chronic phase at the age of 13 all relevant analyzes. During the past 26 years, all modalities of CGL treatment were applied in patients, according to the time period, concluding with the second generation resulting in complete remission of diseases with excellent quality of life and identical expectations for the future, as well as in healthy population.

Development of Therapy Approach in Patient with Chronic Granulocity Leukemia: Case Report

Experimental and Applied Biomedical Research (EABR)

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Chronic granulocytic leukemia (CGL), Ph + is a chronic myeloproliferative disorder, which, due to its specificity for many decades, has attracted the attention...

Development of Therapy Approach in Patient with Chronic Granulocity Leukemia: Case Report

Pubblicato online: 27 feb 2022

Pagine: -

Ricevuto: 17 dic 2018

Accettato: 30 dic 2018

DOI: https://doi.org/10.2478/sjecr-2018-0074

Parole chiave
Chronic granulocytic leukemia, Ph + (CGL), Therapeutic approaches, case report

© 2018 Predrag Krstić et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Development of Therapy Approach in Patient with Chronic Granulocity Leukemia: Case Report

Pubblicato online: 27 feb 2022

Pagine: -

Ricevuto: 17 dic 2018

Accettato: 30 dic 2018

DOI: https://doi.org/10.2478/sjecr-2018-0074

Parole chiaveChronic granulocytic leukemia, Ph + (CGL), Therapeutic approaches, case report

© 2018 Predrag Krstić et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
Chronic granulocytic leukemia, Ph + (CGL), Therapeutic approaches, case report